News & Events
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
Crinetics to showcase pipeline advancements with neuroendocrine tumor candidates at the 2024 NANETS Annual Meeting.
READ MORECrinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Crinetics Pharmaceuticals reported third quarter 2024 financial and provided a business update on clinical progress.
READ MORECrinetics Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 99,500 shares of its common stock to eleven new...
READ MORECrinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024
Event Date: November 12, 2024
READ MORECrinetics Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 258,800 shares of its common stock to twenty-seven new...
READ MORECrinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
Crinetics announces the pricing of an upsized underwritten public offering of 10,000,000 shares of its common stock at a price...
READ MORECrinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
Crinetics announces that it intends to offer and sell, subject to market and other conditions, $400.0 million of shares of...
READ MORECrinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
Crinetics announces the submission of a New Drug Application to the FDA for its investigational drug, paltusotine, for the treatment...
READ MORE2024 Cantor Global Healthcare Conference
Event Date: September 18, 2024
READ MORECrinetics Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 120,000 shares of its common stock to fifteen new...
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
